Cell therapies at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

6 organizations at ENA 2026 present work in cell therapies (CAR-T, TCR), led by cancer centres and hospitals. Between them they bring 26 presentations to the program. Most represented: Vall d'Hebron Institute of Oncology (VHIO), National Cancer Institute (NCI) and University of California, San Francisco. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–6 of 6 organizations

Organization	ENA 2026 Attendance
Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain
vhio.net Cancer centres & hospitals Barcelona cancer research institute at Vall d'Hebron University Hospital, combining translational research with an early-phase clinical trials unit.	Session Wed Nov 18 1:30–1:35pm Opening Ceremony: Welcome and opening of the ENA 2026 Symposium Session Wed Nov 18 1:35–2:20pm Keynote Lecture: The rise of biotech in APAC Session Wed Nov 18 2:20–3:50pm Plenary Session 1: The next wave of immune engagers in cancer therapy: beyond CD3 and beyond T cells Immuno-oncology Talk Thu Nov 19 3:20–3:40pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Targeting YAP/TEAD as monotherapy and in rational combinations Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Phase Ib study of OMO-103 in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma Targeted agents Session Fri Nov 20 8–9:30am Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Cell therapy Talk Fri Nov 20 8:40–9am Part of Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Neoantigen TCR-T Cell therapy Talk Fri Nov 20 9:45–10am Part of Workshop 7: Novel Methodologies & Endpoints in New Drug Development Multi-omics including Spatial Transcriptomics Early clinical Talk Fri Nov 20 12–12:10pm Part of Plenary Session 6: Proffered papers MYC Inhibition with OMO-103 Restores TNF-Superfamily Signaling and Uncovers Actionable Immunotherapy Vulnerabilities in KRAS-Mutant NSCLC Targeted agents · Immuno-oncology Session Fri Nov 20 3–4:50pm Plenary Session 7: Proffered papers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Novel clinical trial design Digital Remote Patient Monitoring in Early-Phase Oncology Clinical Trials: A Prospective Pilot Study of Feasibility and Implementation Early clinical Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models A preclinical patient-derived xenograft platform to model resistance to cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in oestrogen receptor-positive breast cancer. Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Integrative molecular profiling of a breast cancer (BC) patient-derived xenograft (PDX) platform for biomarker discovery Preclinical models
National Cancer Institute (NCI) Bethesda, Maryland
cancer.gov Agencies, groups & societies Federal agency within NIH that funds and conducts cancer research, including intramural labs and clinical trials.	Session Wed Nov 18 1:30–1:35pm Opening Ceremony: Welcome and opening of the ENA 2026 Symposium Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Comparison of CRISPR screens in two- and three-dimensional ovarian cancer models to identify architecture-dependent mechanisms of resistance to CHEK1 inhibition Targeted agents Session Thu Nov 19 10–11:30am Plenary Session 3: Proffered Papers Session Thu Nov 19 5–6:30pm Workshop 6: Tumour microenvironment Immuno-oncology Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology A novel virus-like drug conjugate for the treatment of cutaneous melanoma Immuno-oncology Session Fri Nov 20 8–9:30am Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Cell therapy Session Fri Nov 20 11:15am–12pm Keynote lecture: Immunotherapy innovations Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies ClpP Agonist-Induced Cellular Senescence Promotes Vulnerability to Apoptosis and Ferroptosis in Triple Negative Breast Cancers Targeted agents
University of California, San Francisco San Francisco, CA
ucsf.edu Universities & institutes Health sciences university in San Francisco with a comprehensive cancer center and an academic medical center.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Molecular profiling A neural gene signature predicts recurrence of resected colorectal cancer liver metastases Genomics Talk Fri Nov 20 8:20–8:40am Part of Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Decoding CAR T cell function with CRISPR activation and interference Cell therapy
Reaction Biology Malvern, PA
reactionbiology.com CROs & CDMOsExhibitor Contract research company offering biochemical, cell-based and in vivo pharmacology services for drug discovery, including kinase profiling.	Booth Exhibiting at Booth 7 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Cellular Therapies Development and validation of a simple functional assay to detect neutralizing antibodies in primate sera for AAV gene therapy stratification Cell therapy
NC National Center for Cancer Immune Therapy (CCIT-DK) Herlev, Denmark
Cancer centres & hospitals National centre at Herlev Hospital that develops and tests cancer immunotherapies, including TIL therapy.	Talk Fri Nov 20 9–9:20am Part of Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Cell therapy: what platforms will survive in 2030? Cell therapy
Paul-Ehrlich-Institut Langen, Germany
pei.de Agencies, groups & societies Federal agency regulating vaccines and biomedicines, including cell and gene therapies.	Talk Fri Nov 20 8–8:20am Part of Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) In Vivo CAR-T Cell therapy